787 / 1835
Rituximab – Anti-CD20 mAb and NHL
•
Revolutionised the treatment of NHL, improving outcome for patients with
B cell malignancies
•
Addition of Rituximab to CHOP chemotherapy in DLBCL (aggressive
lymphoma) survival increased for the first time in 25 years (Coiffier et al
NEJM 2002)
•
Rituximab - chemotherapy in FL (indolent lymphoma) dramatically
increased relapse free survival and Overall survival (Marcus et al Blood
2005). Now given as maintenance every 2-3 months for 2 years after
induction therapy (Salles et Lancet 2011)